Members-only Site   |   Print Page   |   Contact Us   |   Sign In   |   Register
IACP Meets with Congress
Share |


 

Cynthia Blankenship, who is employed by Rose Law Firm and recently rejoined IACP, and David Pore of Arnold and Porter, IACP's DC legislative counsel, went to the Hill to meet with Congress last week on behalf of compounding pharmacists.

 

Congress' recently passed Omnibus bill includes language requested by IACP members that mandates FDA to issue guidance within 90 days allowing office-use compounding, prohibits FDA from restricting dispensing practices under the MOU, and mandates FDA to report to Congress within 90 days regarding the finalization of the positive bulk ingredient lists. Cynthia and David met with Appropriators to thank them for continuing to be champions for compounding pharmacists.

 

The Senate Appropriations Committee also was successful in denying all FDA's requests for increased funding in implementing the DQSA compounding provisions. This language could not have been possible without the dedication of our Congressional champions.

 

Your IACP Board of Directors, led by your current Chairman and President, Dale Coker, RPh, FIACP, and Gary McCrory, RPh, CCN, respectively, worked diligently to monitor this issue, designated this appropriations language as a top priority and provided examples and data needed by Congress. 

 

The IACP Legislative Committee, led by Erik Tosh, BS, RPh, FIACP, FACA, worked around the clock to provide input and edits to proposed language and act as a resource to Congress. For a full description of the language included in the Omnibus Appropriations language, please click here.  

In addition, the House Oversight Committee will be hosting a drug pricing hearing at the end of January or early February. As such Cynthia and David met with the House Oversight Committee to act as a resource and offer any assistance needed. This is an issue that IACP has been active on and IACP's Reimbursement Committee led by Baylor Rice, RPh, FIACP, has been diligently monitoring and acting proactively to respond to all issues that continue to come to light on this issue. IACP was successful in getting statements on the record during the Senate Aging Committee hearing expressing that compounding is a solution to the problem of drastically increasing generic drugs. For the full testimony highlights from the Senate Aging Committee as well as a complete packet on all the Congressional action on drug pricing thus far, please click here.

Cynthia and David also met with Congressional pharmacy champions on all Congressional Committees of jurisdiction including House Energy and Commerce. Cynthia and David continue to work with Senator Vitter's office on S 1406 to solicit more cosponsors, and pharmacy champions within the House and Senate on holding FDA accountable for providing guidance allowing office-use within 90 days of enactment pursuant to the Omnibus legislation.  

IACP also led the DQSA Coalition meeting last week, where the Coalition approved a letter to go out to State Boards of Pharmacy and Medicine educating States on the language included within the recently passed Omnibus legislation and asking for their help in ceasing activity on a State level to prohibit office-use compounding and to help hold FDA accountable for releasing guidance allowing office-use compounding. 

 

The letter was signed by more than a dozen pharmacy and physician national organizations as well as more than 20 State Boards of Pharmacy. The letters were sent via mail to all State Boards of Pharmacy and Medicine this past week.

 

Please click here to view a final letter to State Boards of Pharmacy and Medicine.

 

Please click here to view IACP's press release on this effort.

 

The DQSA Coalition will continue working on this issue and has agreed to send a letter regarding the Omnibus language to both FDA and Congress. The DQSA Coalition currently is undertaking efforts to draft these letters with the intent of finalizing in the next week. 

 

The Coalition also will be acting as a resource to Congress as Congress sends a letter to FDA on this issue. The DQSA Coalition continues to grow in size with more organizations joining last week. It now includes 30 organizations representing physician, pharmacy, and patient concerns.  

Thank you for your continued support of IACP. Your support makes the continued efforts with Congress and the DQSA Coalition possible! Please email iacpinfo@iacprx.org if you have any questions.

Association Management Software Powered by YourMembership.com®  ::  Legal